ducovest

SH0:F:F-Shionogi & Co. Ltd (EUR)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 40

Change

0.00 (0.00)%

Market Cap

USD 11.31B

Volume

50.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug. It also develops S-872600 an influenza nasal vaccine; S-875670 anCOVID-19 nasal vaccine; S-540956 a nucleic acid adjuvant; S-554110 a nontuberculous mycobacterial infection; S-337395 for RSV infections; S-892216 for COVID-19 therapeutics; Olorofim for invasive aspergillosis; cefiderocol for aerobic gram-negative bacterial infections and infectious diseases; S-268019 a COVID-19 prophylactic vaccine; S-268019 a prophylactic vaccine for COVID-19; ensitrelvir for COVID-19 treatment and prevention; baloxavir for influenza virus infection; S-365598 for HIV infection; and S-555739 for suppressing aggravation of COVID-19. In addition, the company develops S-540956 for nucleic acid adjuvant; S-109802 for post-stroke spasticity; S-151128 for chronic pain; S-588210 and S-531011 for solid tumor; S-309309 for obesity; BPN14770 for Alzheimer's disease and fragile X syndrome; S-588410 for bladder cancer; S-488210 for head and neck squamous cell carcinoma; S-005151 for Acute ischemic stroke and epidermolysis bullosa; Rizmoic for opioid-induced constipation; ADR-001 for decompensated liver cirrhosis; S-222611 for malignant tumor; S-812217 for depression; GRT7039 for pain associated with osteoarthritis of the knee; SDT-001 for inattentive ADHD; S-588410 for esophageal cancer; SR-0379 for cutaneous ulcer; and S-723595 for type 2 diabetes. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.

Company Website : https://www.shionogi.com

Currency: EUR

Country : Germany

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-22 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
MRKC:F MERCK KGAA NAM.SP.ADR

N/A

 USD 73.13B
MRK:F Merck & Company Inc

N/A

 USD 72.76B
H6D0:F Haleon PLC

N/A

 USD 42.81B
H6D:F Haleon PLC

N/A

 USD 42.44B
TKDA:F Takeda Pharmaceutical Company ..

N/A

 USD 41.84B
TEV:F Teva Pharmaceutical Industries..

N/A

 USD 18.06B
3KY:F HANSOH PHARMAC. HD-00001

N/A

 USD 13.31B
RDDA:F Dr. Reddy's Laboratories Limit..

N/A

 USD 12.12B
NB3:F Neurocrine Biosciences Inc

N/A

 USD 10.87B
EII:F Eisai Co. Ltd

N/A

 USD 10.32B

ETFs Containing SH0:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -6.54% 45% F 39% F
Dividend Return 175.23% 87% B+ 90% A-
Total Return 168.69% 95% A 94% A
Trailing 12 Months  
Capital Gain -2.91% 52% F 43% F
Dividend Return 364.08% 91% A- 92% A
Total Return 361.17% 98% N/A 96% N/A
Trailing 5 Years  
Capital Gain -19.26% 49% F 30% F
Dividend Return 738.80% 81% B- 89% A-
Total Return 719.54% 88% B+ 93% A
Average Annual (5 Year Horizon)  
Capital Gain -2.82% 54% F 37% F
Dividend Return 146.65% 96% N/A 96% N/A
Total Return 149.46% 92% A 93% A
Risk Return Profile  
Volatility (Standard Deviation) 128.26% 7% C- 8% B-
Risk Adjusted Return 114.33% 99% N/A 98% N/A
Market Capitalization 11.31B 96% N/A 87% B+

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector